Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
CD19-directed allogeneic CAR T-cell therapy

zugocabtagene geleucel

An investigational treatment for MOG Antibody-Associated Disease, Neuromyelitis Optica, Multiple Sclerosis, Stiff Person Syndrome, Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia and Mantle Cell Lymphoma.

Phase 2by CRISPR Therapeutics
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Drug facts

The same compound appears under different names depending on the context. Here is how to identify zugocabtagene geleucel wherever you encounter it, plus the key facts at a glance.

Generic name
zugocabtagene geleucel
Development codes
CTX112, zugo-cel
Drug class
CD19-directed allogeneic CAR T-cell therapy
Manufacturer
CRISPR Therapeutics
How it's taken
Infusion into a vein after chemotherapy, in a trial only

An investigational CAR T-cell therapy from CRISPR Therapeutics, made from donor T cells rather than a person's own, that is built to find and clear B cells carrying the marker CD19[5].

  • CRISPR now calls it zugocabtagene geleucel, or zugo-cel, and describes it as formerly CTX112[5].
  • For MOGAD it is in a Phase 1/2 trial (NCT07804004) for adults with relapsing MOGAD and 4 other neurologic autoimmune diseases, which ClinicalTrials.gov listed on November 21, 2026 as not yet recruiting, with no sites named[1].
  • CRISPR described the trial as a Phase 1 study that is enrolling in releases dated November 2 and 8, 2026[5][6].
  • No results in MOGAD have been reported, and CTX112 is not approved anywhere for any use.
Follow zugocabtagene geleucel by email

We'll email you when the FDA acts on zugocabtagene geleucel and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get, for MOG Antibody-Associated Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where zugocabtagene geleucel fits

CTX112, which CRISPR Therapeutics now calls zugo-cel, is an experimental donor-derived CAR T-cell therapy in a Phase 1/2 trial (NCT07804004) that includes adults with relapsing MOGAD, and ClinicalTrials.gov lists that trial as not yet recruiting with no sites named[1][5].

  • MOGAD has no FDA-approved treatment[10], and attacks are usually treated with intravenous steroids, plasma exchange or IVIG, according to NORD[9].
  • Medicines used in the United States to prevent MOGAD relapses, such as mycophenolate, rituximab, azathioprine and repeated IVIG, are prescribed off-label, NORD notes[9].
  • Enspryng (satralizumab) from Genentech is under FDA priority review for MOGAD, with a decision expected by January 10, 2027[10].
  • The CTX112 trial's main measure is safety, counted as dose-limiting side effects in the 28 days after the infusion, and for MOGAD the trial also tracks the yearly relapse rate for up to 24 months[1].
  • No MOGAD results for CTX112 have been reported, and CTX112 has not been compared with Enspryng or any other MOGAD treatment in a trial[1].
  • A question to bring to a neurologist who specializes in neuroimmunology is whether a person's relapse history and current preventive treatment would fit an early-stage CAR T trial that requires chemotherapy beforehand[1].

How zugocabtagene geleucel works

In MOGAD the immune system makes antibodies against MOG, a protein on the myelin coating of nerves in the optic nerves, spinal cord and brain, and attacks of inflammation follow[9]. Antibodies are made by B cells and the cells they mature into, and CTX112 targets CD19, a protein on the surface of B cells[5].

CTX112 starts with T cells from a healthy donor, not from the patient. CRISPR Therapeutics says it uses CRISPR/Cas9 gene editing to switch off certain genes and to insert a chimeric antigen receptor, or CAR, that locks onto CD19, and that the edits are meant to help the cells avoid the recipient's immune system and work more strongly[5]. CRISPR calls it an off-the-shelf therapy given without HLA matching, meaning the donor's tissue type does not have to match the patient's[5].

Before the infusion, people receive lymphodepleting chemotherapy, a short course of chemotherapy that makes room for the infused cells[1][5]. The trial tracks B cell numbers in the blood and CTX112 levels for up to 24 months[1]. Whether clearing B cells this way prevents MOGAD relapses is what the trial is meant to start testing.

Clinical trial results

NCT07804004 is an open-label, single-group Phase 1/2 dose evaluation trial with no placebo or comparison group, run by CRISPR Therapeutics[1]. It plans about 220 adults in all across 5 diseases: progressive multiple sclerosis, relapsing NMOSD, relapsing MOGAD, refractory autoimmune encephalitis and refractory stiff person syndrome. The registry does not say how many places go to MOGAD[1].

CRISPR names NMDAR and LGI1 as the autoimmune encephalitis types included[5]. Adults must be at least 18 and younger than 70 at screening and weigh more than 40kg, with a confirmed diagnosis of relapsing MOGAD for that group[1]. The main measure is safety, counted as dose-limiting side effects in the 28 days after the infusion. For the MOGAD group, the yearly relapse rate is a secondary measure at months 6, 12, 18 and 24[1].

ClinicalTrials.gov gives an estimated start of November 1, 2026 and an estimated completion of December 30, 2029, and listed no sites or contacts as of November 21, 2026[1]. CRISPR said on November 2, 2026 that enrollment in its autoimmune trials is ongoing globally and did not name sites[5].

CTX112 is also in 3 other trials. A Phase 1 trial in lupus, lupus nephritis, systemic sclerosis and inflammatory myositis (NCT06925542) is recruiting at sites in the US, Germany and Spain[2]. CRISPR reported on November 8, 2026 that 5 of 6 people with systemic sclerosis who had standard chemotherapy beforehand met a composite response measure at month 3, that all 9 people with myositis had a moderate or major response, and that 2 of 3 evaluable people with lupus stayed in drug-free remission through at least month 9[6].

These are company figures from small groups with no comparison arm, in diseases other than MOGAD. A Phase 1/2 trial in immune thrombocytopenia and warm autoimmune hemolytic anemia (NCT07549698) is recruiting in Boston, Rochester (Minnesota) and Omaha, and in Germany and Spain[3]. A Phase 1/2 trial in B-cell cancers, including mantle cell lymphoma (NCT05643742), is recruiting in Kansas, Missouri, Texas and Utah, and in Australia[4].

CRISPR said on November 4, 2026 that it would present large B-cell lymphoma data at the American Society of Hematology meeting on December 13, 2026[7].

Main registered trial: NCT07804004 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.

Side effects and safety

Early trial safety observations
Most common in trials
No MOGAD safety data yetIn 21 people with lupus, systemic sclerosis or myositis, CRISPR reported no cytokine release syndrome above grade 2 and no ICANS as of October 15, 2026
What gets monitored
  • Dose-limiting side effects in the 28 days after the infusion, the trial's main measure
  • B cells and CTX112 levels in the blood for up to 24 months
In context

No safety results from CTX112 in MOGAD or any other neurologic disease have been reported. In people with lupus, systemic sclerosis and inflammatory myositis, CRISPR Therapeutics reported on November 8, 2026 that 21 people had been dosed as of October 15, 2026 and that the treatment had been well tolerated in all of them[6].

The company reported no dose-limiting side effects, no cytokine release syndrome above grade 2, no ICANS (a nerve-related CAR T side effect), no IEC-HS (a rare overactive immune reaction), no severe infections, no prolonged low blood counts, no graft-versus-host disease and no deaths to date[6]. These figures come from a company release, not a peer-reviewed paper, and dose escalation is still under way[6].

The MOGAD trial leaves out people who have had any gene or modified cell therapy, any organ or stem cell transplant, a cancer in the last 5 years, a condition needing uninterrupted blood thinners, or a suicide attempt in the last 3 years, and people who are pregnant or breastfeeding[1]. No clinical hold has been reported. Any warnings for an approved product would be set by an FDA label.

These are the safety findings reported so far, often by the company running the trials, not a complete safety picture. A study team or doctor can explain what to expect.

Taking zugocabtagene geleucel

Given in trials only, as an infusion into a vein after lymphodepleting chemotherapy[1]. CRISPR Therapeutics says the cells come ready-made from donors and need no HLA matching, so there is no collection of the patient's own cells[5]. In the rheumatology trial, CRISPR reported dose levels of 100 million and 200 million CAR-positive cells[6]. The doses, the chemotherapy drugs and the number of infusions for the neurologic trial have not been published.

Development history

The Phase 1/2 trial of CTX112 in B-cell cancers began on March 10, 2023, according to ClinicalTrials.gov[4]. In a January 13, 2025 release, CRISPR Therapeutics said CTX112 had received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA based on early data from that cancer trial, and that it was expanding into autoimmune disease[8].

The autoimmune trial in lupus, systemic sclerosis and myositis started on March 10, 2025, and the trial in immune thrombocytopenia and warm autoimmune hemolytic anemia started on July 17, 2026[2][3]. The neurologic trial that includes MOGAD was first posted on ClinicalTrials.gov on September 4, 2026[1]. By November 2, 2026 CRISPR was calling the therapy zugocabtagene geleucel (zugo-cel)[5]. CRISPR has not announced an FDA designation for CTX112 in MOGAD.

Access and eligibility

Manufacturer
CRISPR Therapeutics
Eligibility requirement

Not approved, and available only in a trial. NCT07804004 is for adults at least 18 and younger than 70 with relapsing MOGAD who weigh more than 40kg and have adequate blood, kidney, liver, heart and lung function[1]. It excludes people who have had any gene therapy or genetically modified cell therapy, any organ or stem cell transplant, another active autoimmune disease or brain condition that could confuse the results, a cancer in the last 5 years (except cancers with low chance of coming back), a need for uninterrupted blood thinners, or a suicide attempt within 3 years. It also excludes anyone who cannot have a lumbar puncture or MRI and anyone pregnant or breastfeeding[1]. ClinicalTrials.gov listed the trial as not yet recruiting with no sites on November 21, 2026, and CRISPR has not named sites[1][5]. No expanded access program is listed[1].

Access program details are provided for informational purposes and may vary based on insurance coverage, geographic location, and individual circumstances. Confirm current eligibility directly with the manufacturer or your specialty pharmacy.

Ask anything about zugocabtagene geleucel
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore MOG Antibody-Associated Disease and Neuromyelitis Optica and Multiple Sclerosis and Stiff Person Syndrome and Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia and Mantle Cell Lymphoma trials

Other MOG Antibody-Associated Disease & Neuromyelitis Optica treatments

Common questions about zugocabtagene geleucel

▸What is zugocabtagene geleucel?

An investigational CAR T-cell therapy from CRISPR Therapeutics, made from donor T cells rather than a person's own, that is built to find and clear B cells carrying the marker CD19[5]. CRISPR now calls it zugocabtagene geleucel, or zugo-cel, and describes it as formerly CTX112[5]. For MOGAD it is in a Phase 1/2 trial (NCT07804004) for adults with relapsing MOGAD and 4 other neurologic autoimmune diseases, which ClinicalTrials.gov listed on November 21, 2026 as not yet recruiting, with no sites named[1]. CRISPR described the trial as a Phase 1 study that is enrolling in releases dated November 2 and 8, 2026[5][6]. No results in MOGAD have been reported, and CTX112 is not approved anywhere for any use.

▸How does zugocabtagene geleucel work?

In MOGAD the immune system makes antibodies against MOG, a protein on the myelin coating of nerves in the optic nerves, spinal cord and brain, and attacks of inflammation follow[9]. Antibodies are made by B cells and the cells they mature into, and CTX112 targets CD19, a protein on the surface of B cells[5].

CTX112 starts with T cells from a healthy donor, not from the patient. CRISPR Therapeutics says it uses CRISPR/Cas9 gene editing to switch off certain genes and to insert a chimeric antigen receptor, or CAR, that locks onto CD19, and that the edits are meant to help the cells avoid the recipient's immune system and work more strongly[5]. CRISPR calls it an off-the-shelf therapy given without HLA matching, meaning the donor's tissue type does not have to match the patient's[5].

Before the infusion, people receive lymphodepleting chemotherapy, a short course of chemotherapy that makes room for the infused cells[1][5]. The trial tracks B cell numbers in the blood and CTX112 levels for up to 24 months[1]. Whether clearing B cells this way prevents MOGAD relapses is what the trial is meant to start testing.

▸What are the side effects of zugocabtagene geleucel?

No safety results from CTX112 in MOGAD or any other neurologic disease have been reported. In people with lupus, systemic sclerosis and inflammatory myositis, CRISPR Therapeutics reported on November 8, 2026 that 21 people had been dosed as of October 15, 2026 and that the treatment had been well tolerated in all of them[6]. The company reported no dose-limiting side effects, no cytokine release syndrome above grade 2, no ICANS (a nerve-related CAR T side effect), no IEC-HS (a rare overactive immune reaction), no severe infections, no prolonged low blood counts, no graft-versus-host disease and no deaths to date[6]. These figures come from a company release, not a peer-reviewed paper, and dose escalation is still under way[6]. The MOGAD trial leaves out people who have had any gene or modified cell therapy, any organ or stem cell transplant, a cancer in the last 5 years, a condition needing uninterrupted blood thinners, or a suicide attempt in the last 3 years, and people who are pregnant or breastfeeding[1]. No clinical hold has been reported. Any warnings for an approved product would be set by an FDA label.

▸How is zugocabtagene geleucel taken?

Given in trials only, as an infusion into a vein after lymphodepleting chemotherapy[1]. CRISPR Therapeutics says the cells come ready-made from donors and need no HLA matching, so there is no collection of the patient's own cells[5]. In the rheumatology trial, CRISPR reported dose levels of 100 million and 200 million CAR-positive cells[6]. The doses, the chemotherapy drugs and the number of infusions for the neurologic trial have not been published.

▸Is zugocabtagene geleucel FDA approved?

zugocabtagene geleucel is currently in phase 2 clinical trials for MOG Antibody-Associated Disease and Neuromyelitis Optica and Multiple Sclerosis and Stiff Person Syndrome and Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia and Mantle Cell Lymphoma. It has not yet received FDA approval.

▸Is CTX112 approved for MOGAD?

No. CTX112 (zugo-cel) is an experimental CAR T-cell therapy, and the only MOGAD study is an early-stage Phase 1/2 trial.

Trial status: ClinicalTrials.gov lists NCT07804004 as not yet recruiting with no sites, while CRISPR Therapeutics says enrollment is ongoing.

Results: None reported in MOGAD.

Other MOGAD news: Enspryng (satralizumab) has an FDA decision for MOGAD expected by January 10, 2027.

Source: ClinicalTrials.gov NCT07804004, CRISPR Therapeutics, November 2, 2026 and Genentech, September 9, 2026

▸Who can join the CTX112 trial for MOGAD?

Adults at least 18 and younger than 70 with relapsing MOGAD who weigh more than 40kg.

Not eligible: Earlier gene or modified cell therapy, any organ or stem cell transplant, a cancer in the last 5 years, a need for uninterrupted blood thinners, a suicide attempt within 3 years, pregnancy or breastfeeding.

Tests: People must be able to have a lumbar puncture and MRI.

Where: No sites listed on ClinicalTrials.gov as of November 21, 2026.

Source: ClinicalTrials.gov NCT07804004

▸Is CTX112 the same as zugo-cel?

Yes. CRISPR Therapeutics now calls CTX112 zugocabtagene geleucel, or zugo-cel.

What it is: A donor-derived CAR T-cell therapy aimed at CD19 on B cells, made with CRISPR/Cas9 gene editing.

Donor match: CRISPR says it needs no HLA matching.

Source: CRISPR Therapeutics, November 2, 2026

▸What results has CTX112 shown in autoimmune disease?

None in MOGAD yet. Early company-reported results come from lupus, systemic sclerosis and myositis.

Safety: CRISPR reported on November 8, 2026 that 21 people had been dosed with no cytokine release syndrome above grade 2, no ICANS and no deaths.

Responses: 5 of 6 people with systemic sclerosis who had standard chemotherapy beforehand met a composite response measure (rCRISS-25) at month 3, and all 9 people with myositis had a moderate or major response.

Caution: Small groups, no comparison arm, not yet in a journal.

Source: CRISPR Therapeutics, November 8, 2026

▸What does the CTX112 MOGAD trial measure?

Its main measure is safety, counted as dose-limiting side effects in the 28 days after the infusion.

MOGAD measure: The yearly relapse rate at months 6, 12, 18 and 24.

Blood tests: B cell counts and CTX112 levels for up to 24 months.

Timeline: Estimated completion December 30, 2029.

Source: ClinicalTrials.gov NCT07804004

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. ClinicalTrials.gov. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease. https://clinicaltrials.gov/study/NCT07804004
  2. ClinicalTrials.gov. A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease. https://clinicaltrials.gov/study/NCT06925542
  3. ClinicalTrials.gov. Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease. https://clinicaltrials.gov/study/NCT07549698
  4. ClinicalTrials.gov. A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies. https://clinicaltrials.gov/study/NCT05643742
  5. CRISPR Therapeutics via BioSpace (GlobeNewswire) · 2026-11-02. CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results. https://www.biospace.com/press-releases/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2026-financial-results
  6. CRISPR Therapeutics · 2026-11-08. CRISPR Therapeutics Provides Update on Zugocabtagene Geleucel (Zugo-cel) in Refractory Rheumatologic Autoimmune Diseases. https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-provides-update-on-zugocabtagene-geleucel-zugo-cel-in-refractory-rheumatologic-autoimmune-diseases
  7. CRISPR Therapeutics · 2026-11-04. CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition. https://crisprtx.com/about-us/press-releases-and-presentations/crispr-therapeutics-to-present-clinical-data-from-zugo-cel-in-large-b-cell-lymphoma-at-the-68th-american-society-of-hematology-ash-annual-meeting-and-exposition
  8. CRISPR Therapeutics via BioSpace (GlobeNewswire) · 2025-01-13. CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 Milestones. https://www.biospace.com/press-releases/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2025-milestones
  9. National Organization for Rare Disorders. MOG Antibody Disease - Symptoms, Causes, Treatment. https://rarediseases.org/rare-diseases/mog-antibody-disease/
  10. Genentech · 2026-09-09. U.S. FDA Grants Priority Review for Genentech's Enspryng for MOGAD, an Autoimmune Disease With No Approved Treatments. https://www.gene.com/media/press-releases/15124/2026-09-09/us-fda-grants-priority-review-for-genent

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow zugocabtagene geleucel by email

We'll email you when the FDA acts on zugocabtagene geleucel and when new trials for the condition you pick open. Unsubscribe anytime.

You'll get, for MOG Antibody-Associated Disease:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site